Abbott Laboratories (ABT)
-NYSE 36.21 
1.30(3.47%) 4:02PM EDT|After Hours
:
36.21 0.00 (0.00%) 6:17PM EDT
| Prev Close: | 37.51 |
|---|
| Open: | 37.21 |
|---|
| Bid: | 36.21 x 100 |
|---|
| Ask: | 36.49 x 300 |
|---|
| 1y Target Est: | 40.72 |
|---|
| Beta: | 0.47 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 36.21 - 37.27 |
|---|
| 52wk Range: | 29.50 - 38.77 |
|---|
| Volume: | 6,744,522 |
|---|
| Avg Vol (3m): | 6,983,730 |
|---|
| Market Cap: | 56.45B |
|---|
| P/E (ttm): | 11.04 |
|---|
| EPS (ttm): | 3.28 |
|---|
| Div & Yield: | 0.56 (1.50%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
Headlines
- Abbott Laboratories (ABT): Today's Featured Health Services Laggardat TheStreet(Wed 5:22PM EDT)
- The Best Healthcare Betat Motley Fool(Tue, Jun 18)
- Supreme Court Permits Antitrust Scrutiny Of Pharma Settlementsat Forbes(Tue, Jun 18)
- Abbott Loves Abbott Laboratories Stockat Motley Fool(Mon, Jun 17)
- Successor To Humira? AbbVie And Galapagos Work On Itat Seeking Alpha(Mon, Jun 17)
- Can Cempra Beat The Superbugs?at Seeking Alpha(Mon, Jun 17)
- Supreme Court decision on generics hits Actavis, but few other drug firmsat MarketWatch(Mon, Jun 17)
- 5 Stocks Raising The Drugs Industry Higherat TheStreet(Mon, Jun 17)
- Abbott Declares Dividend and $3 Billion Buyback Planat Motley Fool(Sat, Jun 15)
- Abbott Progresses with Absorb in JapanZacks(Fri, Jun 14)
- Daily Dividend Report: ABT, LHO, DX, AT, RLJat Forbes(Fri, Jun 14)
- 1 Huge Opportunity for the Star Stent of the Futureat Motley Fool(Fri, Jun 14)
- Abbott Announces New $3 Billion Share Repurchase Program, Declares DividendPR Newswire(Fri, Jun 14)
- Should You Buy This Dividend Aristocrat?at Motley Fool(Fri, Jun 14)
- As top court invalidates some gene patents, biotech has moved onat Reuters(Thu, Jun 13)
Key Statistics
| Forward P/E (1 yr): | 16.09 |
|---|
| P/S (ttm): | 1.46 |
|---|
| Ex-Dividend Date: | 11-Apr-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.01 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.44 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 1.55 |
|---|
Business Summary
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine ins...
View More